Market Overview:
The global blood biological products market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of chronic diseases, increasing demand for plasma-derived products, and technological advancements in the field of blood transfusion. The global blood biological products market is segmented on the basis of type into coagulation factor, immune globulin, albumin, and other products. Coagulation factor accounted for the largest share of the global market in 2017 owing to its high usage in hemophilia treatment. Immunoglobulin is expected to grow at a highest CAGR during the forecast period due to its increasing demand for prophylactic therapy against infections caused by pathogens such as hepatitis A & B viruses (HAV & HBV), human immunodeficiency virus (HIV), and varicella zoster virus (VZV). Albumin held second largest share of this market due its extensive use as a volume expander or plasma replacement product across various applications including critical care medicine, surgery patients requiring large volumes resuscitation etc. On the basis application,the global blood biologicals productmarketis segmentedinto immunology,, hematology,,and otherapplications .
Product Definition:
Blood Biological products are derived from blood, they can be purified to a certain extent. They include clotting factors, albumin and other proteins. Blood biological products are important because they help with the clotting of blood and the maintenance of osmotic pressure.
Coagulation Factor:
Coagulation factor is a protein hormone that helps in the clotting of blood. It's produced by the liver and is responsible for controlling bleeding. The normal level of Coagulation Factor in humans is 10-15 times greater than the concentration found in human plasma.
Global Coagulation Factor, it's usage.
Immune Globulin:
Immune Globulin is a plasma protein, which plays an important role in the immune response. It is used as a blood substitute for replacing blood volume lost due to severe bleeding or injury. Immune globulin products are widely used in the treatment of various diseases such as immune deficiency disorders and cancer.
Application Insights:
The other application segment accounted for the largest revenue share in 2017 and is anticipated to witness significant growth over the forecast period. Other applications include proteomics, genomic, pharmacogenomics and toxicology testing. The growing demand for these tests is expected to drive market growth during the forecast period.
On basis of application, the global market has been divided into immunology, hematology and others. Immunological tests accounted for a major share in 2017 owing to an increase in demand from various end-use industries such as diagnostics laboratories & hospitals; autoimmune disease research institutes; pharmaceutical companies; biotechnology firms; etc. This segment is also anticipated to grow at a lucrative rate over the next seven years due to increasing R&D activities pertaining immunity-based drugs coupled with an increase in prevalence of chronic diseases that requireimmunization therapy such as cancer & diabetes (Travis et al., 2015).
Regional Analysis:
North America dominated the global market in 2017. The presence of well-established healthcare infrastructure, high adoption rate of advanced therapies and increasing prevalence of chronic diseases are some factors responsible for its large share. In addition, growing number of biopharmaceutical companies is also expected to contribute towards the growth during the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising investment by government as well as private players in developing R&D facilities and improving healthcare infrastructure in this region.
Moreover, favorable regulatory policies regarding approval.
Growth Factors:
- Increasing incidence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyles and dietary habits of people across the world. As a result, there is an increased demand for blood biological products for diagnosis and treatment of various chronic diseases.
- Technological advancements in blood biological products: There has been a significant advancement in technology used for manufacturing blood biological products in recent years. This has led to the development of new and improved products that are more effective in treating various medical conditions.
- Growing awareness about benefits of blood biological products: There is growing awareness among people about the benefits associated with using blood biological products for diagnosis and treatment purposes. This is helping to drive demand for these products worldwide.
Scope Of The Report
Report Attributes
Report Details
Report Title
Blood Biological Products Market Research Report
By Type
Coagulation Factor, Immune Globulin, Albumin, Other
By Application
Immunology, Hematology, Other
By Companies
Takeda, CSL, Grifols, Octapharma, Kedrion, LFB Group, Biotest, BPL, RAAS, CBPO, Hualan Bio
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
209
Number of Tables & Figures
147
Customization Available
Yes, the report can be customized as per your need.
Global Blood Biological Products Market Report Segments:
The global Blood Biological Products market is segmented on the basis of:
Types
Coagulation Factor, Immune Globulin, Albumin, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Immunology, Hematology, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Takeda
- CSL
- Grifols
- Octapharma
- Kedrion
- LFB Group
- Biotest
- BPL
- RAAS
- CBPO
- Hualan Bio
Highlights of The Blood Biological Products Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Coagulation Factor
- Immune Globulin
- Albumin
- Other
- By Application:
- Immunology
- Hematology
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Blood Biological Products Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Blood Biological Products is a term used to describe any product derived from blood, including plasma, platelets, red blood cells and white blood cells.
Some of the major players in the blood biological products market are Takeda, CSL, Grifols, Octapharma, Kedrion, LFB Group, Biotest, BPL, RAAS, CBPO, Hualan Bio.
The blood biological products market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Blood Biological Products Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Blood Biological Products Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Blood Biological Products Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Blood Biological Products Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Blood Biological Products Market Size & Forecast, 2020-2028
4.5.1 Blood Biological Products Market Size and Y-o-Y Growth
4.5.2 Blood Biological Products Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Coagulation Factor
5.2.2 Immune Globulin
5.2.3 Albumin
5.2.4 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Immunology
6.2.2 Hematology
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Blood Biological Products Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Blood Biological Products Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Coagulation Factor
9.6.2 Immune Globulin
9.6.3 Albumin
9.6.4 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Immunology
9.10.2 Hematology
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Coagulation Factor
10.6.2 Immune Globulin
10.6.3 Albumin
10.6.4 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Immunology
10.10.2 Hematology
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Coagulation Factor
11.6.2 Immune Globulin
11.6.3 Albumin
11.6.4 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Immunology
11.10.2 Hematology
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Coagulation Factor
12.6.2 Immune Globulin
12.6.3 Albumin
12.6.4 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Immunology
12.10.2 Hematology
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Coagulation Factor
13.6.2 Immune Globulin
13.6.3 Albumin
13.6.4 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Immunology
13.10.2 Hematology
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Blood Biological Products Market: Competitive Dashboard
14.2 Global Blood Biological Products Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Takeda
14.3.2 CSL
14.3.3 Grifols
14.3.4 Octapharma
14.3.5 Kedrion
14.3.6 LFB Group
14.3.7 Biotest
14.3.8 BPL
14.3.9 RAAS
14.3.10 CBPO
14.3.11 Hualan Bio
